The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients

Journal of Palliative Medicine

Volumn 15, Issue 1, 2012, Pages 20-24

  Yennurajalingam, Sriram ^a   Atkinson, Bradley ^a   Masterson, Jessica ^a   Hui, David ^a   Urbauer, Diana ^a   Tu, Shi Ming ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; DOCETAXEL; LAXATIVE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OPIATE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANXIETY; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE ACTIVITY; DISEASE SEVERITY; DROWSINESS; ETHNICITY; FATIGUE; FOLLOW UP; HUMAN; INFORMATION PROCESSING; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; OUTPATIENT CARE; PAIN; PALLIATIVE THERAPY; PROSTATE CANCER; RATING SCALE; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SOMNOLENCE; WELLBEING;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; COST OF ILLNESS; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PALLIATIVE CARE; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; TEXAS;

EID: 84856241418     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2011.0219     Document Type: Review

References (30)

1. American Cancer Society: Cancer Facts & Figures 2009. Atlanta: American Cancer Society, 2009.
2. Levy MH, Back A, Bazargan S, Benedetti C, Billings JA, Block S, Bruera E, Carducci MA, Dy S, Eberle C, Foley KM, Harris JD, Knight SJ, Milch R, Rhiner M, Slatkin NE, Spiegel D, Sutton L, Urba S, Von Roenn JH, Weinstein SM; National Comprehensive Cancer Network: Palliative care. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006;4:776-818. (Pubitemid 44412395)
3. Loblaw DA, Virgo KS, Somerfield MR, Ben-Josef E, Men-delson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Ta-plin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI; American Society of Clinical Oncology: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25):1596-1605. (Pubitemid 46733088)
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and pred-nisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520. (Pubitemid 39315318)
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Ro-senthal MA, Eisenberger MA; TAX 327 Investigators: Doc-etaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512. (Pubitemid 39315317)
6. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K: The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Pal-liat Care 1991;7:6-9.
7. Elsayem A DL, Bruera E: The M.D. Anderson Symptom Control and Palliative Care Handbook, 3rd ed. Houston: University of Health Science Center at Houston, 2008.
8. Thompson JC, Wood J, Feuer D: Prostate cancer: Palliative care and pain relief. Br Med Bull 2007;83:341-354. (Pubitemid 47614260)
9. Bauman G, Charette M, Reid R, Sathya J: Radio-pharmaceuticals for the palliation of painful bone metastasis: A systemic review. Radiother Oncol 2005;75:258-270.
10. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M: Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798-804. (Pubitemid 40909122)
11. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD: Bispho-sphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006;(4):CD006250.
12. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus pred-nisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764. (Pubitemid 26185452)
13. Logothetis CJ, Millikan R: Chemotherapy for advanced prostate cancer: 25 years later. J Clin Oncol 2008;26:2423-2424.
14. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ: Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742.
15. Dalal S, Palla S, Hui D, Nguyen L, Chacko R, Li Z, Fadul N, Scott C, Thornton V, Coldman B, Amin Y, Bruera E: Association between a name change from palliative to supportive care and the timing of patient referrals at a comprehensive cancer center. Oncologist 2011;16:105-111.
16. Osta BE, Palmer JL, Paraskevopoulos T, Pei BL, Roberts LE, Poulter VA, Chacko R, Bruera E: Interval between first palliative care consult and death in patients diagnosed with advanced cancer at a comprehensive cancer center. J Palliat Med 2008;11:51-57.
17. Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mu-kaiyama T, Nakaho T, Nakashima N, Shima Y, Matsubara T, Uchitomi Y: Late referrals to specialized palliative care service in Japan. J Clin Oncol 2005;23:2637-2644. (Pubitemid 46179452)
18. World Health Organization Palliative Care Definition. World Health Organization, 2009. www.who.int/cancer/palliative/definition/en/Last accessed July 23, 2011.
19. Morrison LJ, Morrison RS: Palliative care and pain management. Med Clin North Am 2006;90:983-1004. (Pubitemid 44348817)
20. Borneman T, Koczywas M, Cristea M, Reckamp K, Sun V, Ferrell B: An interdisciplinary care approach for integration of palliative care in lung cancer. Clin Lung Cancer 2008;9: 352-360.
21. Fadul N, Elsayem A, Palmer JL, Del Fabbro E, Swint K, Li Z, Poulter V, Bruera E: Supportive versus palliative care: What's in a name?: A survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer 2009;115:2013-2021.
22. Dawson NA, McLeod DG: The assessment of treatment outcomes in metastatic prostate cancer: Changing endpoints. Eur J Cancer 1997;33:560-565. (Pubitemid 27223738)
23. The NCCN Clinical Practice Guidelines in Oncology™ Cancer-Related Fatigue. © 2010 National Comprehensive Cancer Network, Inc. www.NCCN.org Last accessed July 23, 2011.
24. Fowler JE Jr, Whitmore WF Jr: The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126:372-375. (Pubitemid 11061000)
25. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M: Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report. J Clin Oncol 1994;12: 1868-1875.
26. Silvestris N, Leone B, Numico G, Lorusso V, De Lena M: Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology 2005;69:273-282. (Pubitemid 41752794)
27. Herr HW, O'Sullivan M: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000;163:1743-1746. (Pubitemid 30366726)
28. Stone P, Hardy J, Huddart R, A'Hern R, Richards M: Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000;36:1134-1141. (Pubitemid 30330912)
29. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E: Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004;100: 851-858. (Pubitemid 38176866)
30. Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, DeGracia B, Willey JS, Bruera E: The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 2006; 107:2949-2957. (Pubitemid 44937051)